Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Jul 11. doi: 10.1007/s00115-019-0760-0. [Epub ahead of print] Review. German.

PMID:
31297574
2.

Autoimmune encephalitis associated with antibodies against the metabotropic glutamate receptor type 1: case report and review of the literature.

Christ M, Müller T, Bien C, Hagen T, Naumann M, Bayas A.

Ther Adv Neurol Disord. 2019 May 10;12:1756286419847418. doi: 10.1177/1756286419847418. eCollection 2019.

3.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Jul 1;76(7):841-849. doi: 10.1001/jamaneurol.2019.0905.

PMID:
31034002
4.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

5.

Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart®.

Rieckmann P, Schwab M, Pöhlau D, Penner IK, Wagner T, Schel E, Bayas A.

Adv Ther. 2019 Jan;36(1):175-186. doi: 10.1007/s12325-018-0839-1. Epub 2018 Nov 28.

PMID:
30488338
6.

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis.

Hammer A, Waschbisch A, Kuhbandner K, Bayas A, Lee DH, Duscha A, Haghikia A, Gold R, Linker RA.

Ann Clin Transl Neurol. 2018 Apr 16;5(6):668-676. doi: 10.1002/acn3.553. eCollection 2018 Jun.

7.

Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica.

Hoffmann F, Kraft A, Heigl F, Mauch E, Koehler J, Harms L, Kümpfel T, Köhler W, Ehrlich S, Bayas A, Weinmann-Menke J, Beuker C, Henn KH, Ayzenberg I, Ellrichmann G, Hellwig K, Klingel R, Fassbender CM, Fritz H, Slowinski T, Weihprecht H, Brand M, Stiegler T, Galle J, Schimrigk S.

Ther Adv Neurol Disord. 2018 May 28;11:1756286418774973. doi: 10.1177/1756286418774973. eCollection 2018.

8.

Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.

Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA.

J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25.

PMID:
29696498
9.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

10.

Role of Nuclear Factor (Erythroid-Derived 2)-Like 2 Signaling for Effects of Fumaric Acid Esters on Dendritic Cells.

Hammer A, Waschbisch A, Knippertz I, Zinser E, Berg J, Jörg S, Kuhbandner K, David C, Pi J, Bayas A, Lee DH, Haghikia A, Gold R, Steinkasserer A, Linker RA.

Front Immunol. 2017 Dec 22;8:1922. doi: 10.3389/fimmu.2017.01922. eCollection 2017.

11.

Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN.

Bayas A, Schuh K, Baier M, Vormfelde SV; REGAIN Study Group.

Ther Adv Neurol Disord. 2016 Sep;9(5):378-88. doi: 10.1177/1756285616651197. Epub 2016 Jun 3.

12.

CEACAM1 mediates B cell aggregation in central nervous system autoimmunity.

Rovituso DM, Scheffler L, Wunsch M, Kleinschnitz C, Dörck S, Ulzheimer J, Bayas A, Steinman L, Ergün S, Kuerten S.

Sci Rep. 2016 Jul 20;6:29847. doi: 10.1038/srep29847.

13.

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.

BMC Neurol. 2016 Jul 12;16:98. doi: 10.1186/s12883-016-0625-0.

14.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

15.

The Correlation between the Virus- and Brain Antigen-Specific B Cell Response in the Blood of Patients with Multiple Sclerosis.

Wunsch M, Hohmann C, Milles B, Rostermund C, Lehmann PV, Schroeter M, Bayas A, Ulzheimer J, Mäurer M, Ergün S, Kuerten S.

Viruses. 2016 Apr 23;8(4):105. doi: 10.3390/v8040105.

16.

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.

Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel KH, Kieseier BC, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill CM, Limmroth V, Linker RA, Loleit V, Meuth SG, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen MM, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Strauch K, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Hemmer B, Ziegler A; German Competence Network for Multiple Sclerosis (KKNMS).

Genet Epidemiol. 2015 Dec;39(8):601-8. doi: 10.1002/gepi.21933. Epub 2015 Oct 26.

PMID:
26497834
17.

The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.

Rovituso DM, Duffy CE, Schroeter M, Kaiser CC, Kleinschnitz C, Bayas A, Elsner R, Kuerten S.

Sci Rep. 2015 Sep 21;5:14265. doi: 10.1038/srep14265.

18.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis.

Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.

PMID:
26362898
19.

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.

Rau D, Lang M, Harth A, Naumann M, Weber F, Tumani H, Bayas A.

Int J Mol Sci. 2015 Jun 29;16(7):14669-76. doi: 10.3390/ijms160714669.

20.

Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.

Bayas A, Ouallet JC, Kallmann B, Hupperts R, Fulda U, Marhardt K; SMART study group.

Expert Opin Drug Deliv. 2015 Aug;12(8):1239-50. doi: 10.1517/17425247.2015.1057567. Epub 2015 Jun 22.

PMID:
26098143
21.

Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence.

Bayas A, Mäurer M.

Patient Prefer Adherence. 2015 Feb 9;9:265-74. doi: 10.2147/PPA.S61651. eCollection 2015. Review.

22.

Natalizumab therapy for highly active pediatric multiple sclerosis.

Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A.

JAMA Neurol. 2013 Apr;70(4):469-75. doi: 10.1001/jamaneurol.2013.923.

PMID:
23420110
23.

Improving adherence to injectable disease-modifying drugs in multiple sclerosis.

Bayas A.

Expert Opin Drug Deliv. 2013 Mar;10(3):285-7. doi: 10.1517/17425247.2013.763793. Epub 2013 Jan 23.

PMID:
23339371
24.

Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions.

Bayas A, Gold R, Naumann M.

J Neurol Sci. 2013 Jan 15;324(1-2):53-6. doi: 10.1016/j.jns.2012.09.033. Epub 2012 Oct 23.

PMID:
23095259
25.

Accidental natalizumab administration in pregnancy in multiple sclerosis.

Bayas A, Penzien J, Hellwig K.

Acta Neurol Scand. 2012 Jul;126(1):e5-6. doi: 10.1111/j.1600-0404.2011.01636.x. No abstract available.

PMID:
22671932
26.

Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis.

Bayas A, Penzien J, Hellwig K.

Acta Neurol Scand. 2011 Oct;124(4):290-2. doi: 10.1111/j.1600-0404.2010.01480.x. Epub 2011 Feb 9.

PMID:
21943035
27.

Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis.

Bayas A, Stasiolek M, Kruse N, Toyka KV, Selmaj K, Gold R.

Clin Exp Immunol. 2009 Sep;157(3):332-42. doi: 10.1111/j.1365-2249.2009.03964.x.

28.

Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis.

Stasiolek M, Bayas A, Kruse N, Wieczarkowiecz A, Toyka KV, Gold R, Selmaj K.

Brain. 2006 May;129(Pt 5):1293-305. Epub 2006 Mar 2.

PMID:
16513684
29.

[Autoimmune neuropathies--current aspects of immunopathologic diagnostics and therapy].

Gold R, Bayas A, Toyka KV.

Nervenarzt. 2005 Aug;76(8):1009-21; quiz 1022-3. Review. German.

PMID:
16080020
30.

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, Chofflon M, Götschi-Fuchs M, Hess K, Kappos L, Kesselring J, Goebels N, Ludin HP, Mattle H, Schluep M, Vaney C, Baumhackl U, Berger T, Deisenhammer F, Fazekas F, Freimüller M, Kollegger H, Kristoferitsch W, Lassmann H, Markut H, Strasser-Fuchs S, Vass K, Altenkirch H, Bamborschke S, Baum K, Benecke R, Brück W, Dommasch D, Elias WG, Gass A, Gehlen W, Haas J, Haferkamp G, Hanefeld F, Hartung HP, Heesen C, Heidenreich F, Heitmann R, Hemmer B, Hense T, Hohlfeld R, Janzen RW, Japp G, Jung S, Jügelt E, Koehler J, Kölmel W, König N, Lowitzsch K, Manegold U, Melms A, Mertin J, Oschmann P, Petereit HF, Pette M, Pöhlau D, Pohl D, Poser S, Sailer M, Schmidt S, Schock G, Schulz M, Schwarz S, Seidel D, Sommer N, Stangel M, Stark E, Steinbrecher A, Tumani H, Voltz R, Weber F, Weinrich W, Weissert R, Wiendl H, Wiethölter H, Wildemann U, Zettl UK, Zipp F, Zschenderlein R, Izquierdo G, Kirjazovas A, Packauskas L, Miller D, Koncan Vracko B, Millers A, Orologas A, Panellus M, Sindic CJ, Bratic M, Svraka A, Vella NR, Stelmasiak Z, Selmaj K, Bartosik-Psujik H, Mitosek-Szewczyk K, Belniak E, Mochecka A, Bayas A, Chan A, Flachenecker P, Gold R, Kallmann B, Leussink V, Mäurer M, Ruprecht K, Stoll G, Weilbach FX; Multiple Sclerosis Therapy Consensus Group.

J Neurol. 2004 Nov;251(11):1329-39. Review.

PMID:
15592728
31.

Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.

Bayas A, Gold R.

J Neurol. 2003 Dec;250 Suppl 4:IV3-8. Review.

PMID:
14712395
32.

[Diagnostic principles in myopathies].

Bayas A, Gold R.

Fortschr Neurol Psychiatr. 2003 Feb;71(2):61-6. Review. German.

PMID:
12579468
33.

Modulation of cytokine mRNA expression by brain-derived neurotrophic factor and nerve growth factor in human immune cells.

Bayas A, Kruse N, Moriabadi NF, Weber F, Hummel V, Wohleben G, Gold R, Toyka KV, Rieckmann P.

Neurosci Lett. 2003 Jan 2;335(3):155-8.

PMID:
12531456
34.

Human cerebral endothelial cells are a potential source for bioactive BDNF.

Bayas A, Hummel V, Kallmann BA, Karch C, Toyka KV, Rieckmann P.

Cytokine. 2002 Jul 21;19(2):55-8. Review.

PMID:
12182839
35.

Characteristic gene expression profile of primary human cerebral endothelial cells.

Kallmann BA, Wagner S, Hummel V, Buttmann M, Bayas A, Tonn JC, Rieckmann P.

FASEB J. 2002 Apr;16(6):589-91.

PMID:
11919163
36.

Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules.

Hummel V, Kallmann BA, Wagner S, Füller T, Bayas A, Tonn JC, Benveniste EN, Toyka KV, Rieckmann P.

J Neuropathol Exp Neurol. 2001 Apr;60(4):320-7.

PMID:
11305867
37.

Managing the adverse effects of interferon-beta therapy in multiple sclerosis.

Bayas A, Rieckmann P.

Drug Saf. 2000 Feb;22(2):149-59. Review.

PMID:
10672896
38.

Meningioma associated with McCune-Albright syndrome.

Bayas A, Naumann M, Wever S, Toyka KV.

J Neurol. 1999 Dec;246(12):1199-200. No abstract available.

PMID:
10653317
39.

Interphase cytogenetics of glioblastoma and gliosarcoma.

Paulus W, Bayas A, Ott G, Roggendorf W.

Acta Neuropathol. 1994;88(5):420-5.

PMID:
7847070

Supplemental Content

Support Center